November 13, 2025

To
The General Manager-Listing
Corporate Relationship Department
BSE Limited, Ground Floor,
P.J. Towers, Dalal Street,
Mumbai-400001

Scrip Code: 524632

Dear Sir/Madam,

Sub: Outcome of the meeting of the Board of Directors held on Thursday, November 13, 2025.
Ref: Regulation 30 & 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirement) Regulation, 2015

Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, the Board of Directors of the at their meeting held on today i.e. Thursday, November 13, 2025 at the Registered Office of the Company ***inter-alia*** has, considered and approved the following: -

1. Un-Audited Financial Results of the Company for the Second Quarter and Half Year ended September 30, 2025, along with the Auditors' Limited Review Reports in accordance with the provisions of Regulation 33 of the SEBI Listing Regulations.

2. Reviewed the business of the company

The Board Meeting commenced at 05.00 p.m. and concluded at 06.00 p.m.

You are requested to take the above information on records and disseminated the same on your respective websites.

Thanking you,
Yours faithfully,

For Shukra Pharmaceuticals Limited

SHUKRA PHARMACEUTICALS LIMITED REG.NO.:- 019079

Bhoomiben Patel
Director
DIN: 08316893

Encl.: a/a

SHUKRA PHARMACEUTICALS LIMITED
CIN: L24231GJ1993PLC019079
3rd Floor, Dev House, Opposite WIAA Institute, Judges Bungalow Road, Bodakdev, Ahmedabad - 380054
Email : info@shukrapharmaceuticals.com
STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2025
(All amounts in ₹ Lakhs, Unless Otherwise Stated)

Sr. No.	Particulars	QUARTER ENDED			HALF YEARLY		Year Ended
		30.09.2025 (Unaudited)	30.06.2025 (Unaudited)	30.09.2024 (Unaudited)	30.09.2025 (Unaudited)	30.09.2024 (Unaudited)	31.03.2025 (Audited)
1	**Income from Operations**						
	Revenue from Operations	587.74	539.11	555.52	1,126.85	873.32	3,258.73
	Other Income	171.26	110.97	101.74	282.23	173.50	420.67
	Total Income from Operations	**759.00**	**650.08**	**657.27**	**1,409.08**	**1,046.83**	**3,679.39**
2	**Expenses**						
	(a) Cost of materials consumed	1,080.81	-124.85	145.19	955.96	237.34	1,174.55
	(b) Purchase of Stock-in Trade	-	-	86.28	-	86.28	-
	(c) Changes in inventories of finished goods, and work-in-progress and stock in trade	-880.33	201.88	6.35	-678.45	-84.13	-363.38
	(d) Employee Benefit Expenses	219.33	182.49	142.90	401.82	281.17	611.01
	(e) Finance Cost	28.50	26.81	11.11	55.31	17.28	59.49
	(f) Depreciation & Amortisation Expenses	80.92	78.72	69.82	159.64	136.33	300.49
	(g) Other Expenses	209.93	147.71	108.12	357.64	205.39	563.57
	Total Expenses	**739.16**	**512.78**	**569.78**	**1,251.92**	**879.67**	**2,345.73**
3	**Profit / (Loss) before Exceptional and Extra ordinary items and Tax (1-2)**	**19.84**	**137.30**	**87.49**	**157.16**	**167.16**	**1,333.66**
4	**Exceptional Items**		-	-	-	-	-
5	**Profit / (Loss) before Extra ordinary items and Tax (3-4)**	**19.84**	**137.30**	**87.49**	**157.16**	**167.16**	**1,333.66**
6	**Extra ordinary items**		-	-	-	-	-
7	**Net Profit / (Loss) from Ordinary Activities before Tax (5-6)**	**19.84**	**137.30**	**87.49**	**157.16**	**167.16**	**1,333.66**
8	**Tax Expenses**						
	I. Current Tax	-0.00	40.59	28.80	40.59	55.40	362.36
	II. Deferred Tax	-217.96	-6.24	4.80	-224.20	9.34	13.78
	II. Tax of Earlier Year	-		-		-	-
	IV. MAT Credit Entitlement	-		-		-	
9	**Net Profit / (Loss) for the Period (7-8)**	**237.81**	**102.96**	**53.89**	**340.77**	**102.42**	**957.51**
10	**Other Comprehensive Income (net of Tax)**						
	Remeasurement of defined benefit plans	-	-	-	-	-	1.08
	Prior Period Adjustments & Expenses	-	-	-	-	-	-
11	**Total Comprehensive Income for the period (9+10)**	**237.81**	**102.96**	**53.89**	**340.77**	**102.42**	**958.59**
12	**Paid up Equity Share Capital**	**4,378.79**	**4,378.79**	**4,378.79**	**4,378.79**	**4,378.79**	**4,378.79**
13	**Face Value of Equity Shares**	**1.00**	**1.00**	**10.00**	**1.00**	**10.00**	**1.00**
14	**Earnings per Share (of Re. 10/- each) :**						
	(a) Basic-Rs	0.05	0.02	0.25	0.08	0.25	0.22
	(b) Diluted-Rs	0.05	0.02	0.25	0.08	0.25	0.22

NOTES:

1. The above Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its Meeting held on 13th November, 2025.The statutory auditors have carried out review of the results for the quarter ended on 30th September, 2025 and have expressed an unqualified audit opinion.
2. The Unaudited Financial Statements are prepared in accordance with the Accounting Standards specified under Section 133 of the Companies Act, 2013 ("Act") read with Companies (Indian Accounting Standards) Rules, 2015 as amended and in the format as prescribed under Regulation 33 of the SEBI (LODR) Regulations, 2015.
3. The Financial Results of the Company are available on Company's website and also on the website of BSE Limited, i.e. www.bseindia.com, where the Shares of the Company are listed.
4. During the quarter ended 30th September, 2025, 0 complaints were received out of that 0 complaints were disposed off at the end of the quarter.
5. The figures for the previous period/year have been regrouped /reclassified , wherever necessary.
6. The Company is operating in single segment, so above results are for single segment only.

SHUKRA PHARMACEUTICALS LIMITED REG.NO.:- 019079

For and on behalf of Board of Directors of,
SHUKRA PHARMACEUTICALS LIMITED

DAKSHESH RAMESHCHANDRA SHAH

Dakshesh Shah
Director
DIN:00561666

DATE: 13/11/2025
PLACE: AHMEDABAD

SHUKRA PHARMACEUTICALS LIMITED
CIN:L24231GJ1993PLC019079
Standalone Balance Sheet As At March 31, 2025
(All amounts in ₹ Lakhs, Unless Otherwise Stated)

Particulars	As at Sep 30, 2025 (Unaudited)	As at March 31, 2025 (Unaudited)
Assets		
Non-current assets		
Property, plant and equipment	1,891.25	1,939.72
Capital work-in-progress	195.49	194.54
	2,086.74	**2,134.26**
Current assets		
Inventories	1,589.57	995.30
Financial assets		
(i) Investments		
(i) Trade receivables	419.03	876.70
(ii) Loans	519.97	1,022.98
(iii) Cash and cash equivalents	1,335.82	1,211.77
(vi) Other financial assets		
Income tax assets (Assets)	84.48	71.51
Other current assets	2,687.75	2,364.44
	6,636.62	**6,542.72**
Total Assets	**8,723.36**	**8,676.98**
Equity and liabilities		
Equity		
Equity share capital	4,378.79	4,378.79
Other equity	2,201.78	1,904.79
	6,580.57	**6,283.59**
Total Equity	**6,580.57**	**6,283.59**
Liabilities		
Non-current liabilities		
Financial liabilities		
(i) Borrowings	267.78	311.29
Deferred tax liabilities (net)	116.85	341.05
Long term provisions	13.54	12.69
	398.17	**665.03**
Current liabilities		
Financial liabilities		
(i) Borrowings	107.82	106.38
(ii) Trade payables	827.47	921.63
Provisions		
Other current liabilities	495.16	426.77
Short term provision	314.17	273.59
	1,744.62	**1,728.36**
Total liabilities	**2,142.79**	**2,393.39**
Total equity and liabilities	**8,723.36**	**8,676.98**

SHUKRA PHARMACEUTICALS LIMITED REG.NO.:- 019079

For and on behalf of Board of Directors of,
SHUKRA PHARMACEUTICALS LIMITED

DAKSHESH RAMESHCHANDRA SHAH

Digitally signed by DAKSHESH RAMESHCHANDRA SHAH
DN: c=IN, postalCode=380007, st=GUJARAT, street=27,JAGANNATH PARK ,NIRAJ PARK ROAD ,AHMEDABAD,OCTROI NAKA ,380051, l=AHMEDABAD, o=Personal, pseudonym=f2e26a229ce80ff1e2035fcd97979764, 2.5.4.65=6f1d7e3dd1c959a2946224, postalAddress=-588b198525,+M2009/S0089/S0004402, 2.5.4.20=8d2737383f2560213d3118bd5226e6c76d7f63b86015cc5e2839f9fdc337751880, email=-DAKSHESH1984@GMAIL.COM, cn=DAKSHESH RAMESHCHANDRA SHAH
Date: 2025.11.13 18:02:28 +05'30'

DAKSHESH RAMESHCHANDRA SHAH

Dakshesh Shah
Director
DIN:00561666

DATE: 13/11/2025
PLACE: AHMEDABAD

SHUKRA PHARMACEUTICALS LIMITED
CIN:L24231GJ1993PLC019079
Statement of Cash Flows for the year ended March 31, 2025
(All amounts in ₹ Lakhs, Unless Otherwise Stated)

Particulars	For the half year ended Sep 30, 2025 (Unaudited)	For the year ended March 31, 2025 (Unaudited)
Cash flow from operating activities		
Profit before tax as per statement of profit and loss	157.16	1,333.66
Adjustments for:		
Depreciation and amortisation	159.64	300.49
Interest income	(70.73)	(147.94)
Interest expense	49.09	59.49
Operating profit before working capital changes	**295.16**	**1,545.70**
Movements in working capital :		
(Increase)/decrease in trade receivables	457.68	1,574.59
(Increase)/decrease in inventories	(594.27)	(763.86)
(Increase)/decrease in other assets	166.74	(1,516.46)
Increase/(decrease) in trade payables	(94.16)	199.49
Increase/(decrease) in other liabilities	70.68	128.53
Cash generated from operations	**301.83**	**1,167.99**
Direct taxes (paid)/refund (net)		(376.15)
Net cash Inflow / (Outflow) from operating activities (A)	**301.83**	**791.84**
Cash flows from investing activities		
Purchase of property, plant and equipments (Including capital work in progress, capital advances	(112.12)	(274.30)
Interest received	70.73	147.94
Net cash inflow from investing activities (B)	**(41.39)**	**(126.36)**
Cash flows from financing activities		
Proceeds from long-term borrowing	(43.51)	45.62
Interest paid	(49.09)	(59.49)
Dividend paid	(43.79)	(437.88)
Net cash Inflow from financing activities (C)	**(136.39)**	**(451.75)**
Net increase / (decrease) in cash & cash equivalents (A + B + C)	124.06	213.72
Cash and cash equivalents at the beginning of the year	1,211.77	998.04
Cash and cash equivalents at the end of the period	**1,335.82**	**1,211.77**
Notes:		
Cash on hand	5.99	39.63
On current accounts	270.60	195.15
As a Overdraft	(835.68)	(765.46)
In fixed deposit	1,894.92	1,742.45
Cash and Cash Equivalents at the End of the period	**1,335.82**	**1,211.77**

(1) The Statement of Cash flows has been prepared under the Indirect method as set out in Ind AS 7 – Statement of Cash flows notified under section 133 of The Companies Act, 2013, read together with paragraph 7 of the Companies (Indian Accounting Standard) Rules 2015 (as amended).

2)The figures for the previous period /year have been regrouped/ reclassified , whenever necessary.

SHUKRA PHARMACEUTICALS LIMITED REG.NO.:- 019079

For and on behalf of Board of Directors of,
SHUKRA PHARMACEUTICALS LIMITED

DAKSHESH RAMESHCHANDRA SHAH

Dakshesh Shah
Director
DIN:00561666

DATE: 13/11/2025
PLACE: AHMEDABAD

INDEPENDENT AUDITOR'S REVIEW REPORT on the Quarterly and half Yearly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To,
The Board of Directors,
SHUKRA PHARMACEUTICALS LIMITED,
Ahmedabad

1. We have reviewed the accompanying statement of unaudited standalone financial results of **SHUKRA PHARMACEUTICALS LIMITED** (the "Company"), for the quarter and Half Year ended September 30, 2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. This Statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (Ind AS) 34 on 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

SHAH SANGHVI & ASSOCIATES ★ CHARTERED ACCOUNTANTS ★ FRN. NO. 140107W

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



For, Shah Sanghvi & Associates
[Firm Registration No.140107W]
Chartered Accountants

Ravi Shah
Partner
Mem no: 149091

Date : 13/11/2025
UDIN : 25149091BMUJJS2156